To investigate the randomized control of buspirone combined with agomelatine in the treatment of de-pression with anxiety symptoms
Objective To investigate the clinical effect and safety of buspirone combined with agomelatine in the treatment of depression with anxiety symptoms.Methods A total of 862 patients with depression with anxiety symptoms admitted to Kailuan Mental Health Center from January 2019 to January 2021 were selected,which met the diagnostic criteria of depression with anxiety symptoms in the Diagnostic and Statistical Manual of Mental Disorders(5th Edition).They were divided into two groups according to random number table method,with 431 patients in each group.Exclud-ing dropout cases,there were 389 cases in the study group and 382 cases in the control group.The study group was given buspirone oral therapy,combined with agomelatine oral therapy;The control group was only given agomelatine oral therapy,and the therapeutic effect of the two groups was compared.Before and 8 weeks after treatment,17-item Ham-ilton Depression Scale(HAMD-17)and Hamilton Anxiety Scale(HAMA)were used to evaluate the emotional state of the patients,sleep quality was evaluated by polysomnogram,and the inflammation state of the patients was evaluated by serum tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6).The adverse reactions of the two groups were analyzed.Results After treatment,the total effective rate of the study group was 90.23％,which was higher than that of the control group(80.63％),the difference was statistically significant(x 2=14.315,P＜0.05).After treatment,the total score of HAMD-17 and HAMA in the study group were(8.62±2.28)points and(7.75±2.29)points,re-spectively,which were lower than those in the control group(11.33±3.15)points and(10.21±2.93)points,and the differences were statistically significant(t=13.702,13.002,P＜0.05).Total sleep time,REM sleep latency and slow wave sleep time were(415.47±40.61)min,(79.19±4.31)min and(33.75±3.23)min,respectively.It was longer than that of control group(393.20±46.14)min,(74.22±5.17)min and(29.72±4.08)min,and the difference was statistically significant(t=7.118,14.509,15.221,P＜0.05).Sleep efficiency was(82.64±3.57)％,higher than that of control group(76.32±5.13)％,the difference was statistically significant(t=19.885,P＜0.05).The number of awakenings＞5 min was(2.24±0.53)times,less than the control group(2.72±0.71)times,the difference was statistically significant(t=10.650,P＜0.05).Serum TNF-α and IL-6 levels were(46.52±10.17)pg/mLand(35.64 ±9.62)pg/mL,respectively,which were lower than those of control group(55.43±13.48)pg/mL and(44.56± 11.08)pg/mL,respectively.The difference was statistically significant(t=10.373,11.943,P＜0.05).Conclusion Buspirone combined with agomelatine can better relieve the adverse emotional state of depression patients with anxiety symptoms,improve the sleep quality and cognitive function of patients,reduce the body inflammatory response,and does not increase the incidence of adverse drug reactions.
NETL
NSTL
万方数据
